MARKET

ALIM

ALIM

Alimera Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.69
+0.54
+8.77%
Opening 12:59 02/20 EST
OPEN
6.37
PREV CLOSE
6.15
HIGH
6.74
LOW
6.37
VOLUME
20.87K
TURNOVER
--
52 WEEK HIGH
18.15
52 WEEK LOW
0.0045
MARKET CAP
498.07M
P/E (TTM)
-2.7360
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ALIM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ALIM News

  • Insider Buying: The Alimera Sciences, Inc. (NASDAQ:ALIM) Just Bought US$562k Worth Of Shares
  • Simply Wall St..01/29 09:52
  • Alimera Sciences, Inc 13D/A filing
  • PR Newswire.01/27 13:11
  • 2 Healthcare Stocks Set to Rally into the New Year
  • TipRanks.01/10 21:11
  • Alimera Sciences Refinances Its Debt Facility With Solar Capital
  • GlobeNewswire.01/06 13:00

More

Industry

Pharmaceuticals
-0.79%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Name
Price
%Change

About ALIM

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through U.S. and International segment. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, Canada, Lebanon and the United Arab Emirates, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
More

Webull offers Alimera Sciences Inc (ALIM) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.